S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
Log in
NASDAQ:BCLI

Brainstorm Cell Therapeutics Competitors

$3.46
-0.05 (-1.42 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.45
Now: $3.46
$3.69
50-Day Range
$3.51
MA: $5.72
$7.88
52-Week Range
$3.10
Now: $3.46
$17.95
Volume340,046 shs
Average Volume1.18 million shs
Market Capitalization$123.59 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37

Competitors

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Vs. FUSN, HARP, AVRO, CBMG, FRLN, and OPT

Should you be buying BCLI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Brainstorm Cell Therapeutics, including Fusion Pharmaceuticals (FUSN), Harpoon Therapeutics (HARP), AVROBIO (AVRO), Cellular Biomedicine Group (CBMG), Freeline Therapeutics (FRLN), and Opthea (OPT).

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Insider and Institutional Ownership

21.6% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 61.4% of Fusion Pharmaceuticals shares are held by institutional investors. 22.1% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Brainstorm Cell Therapeutics and Fusion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Brainstorm Cell Therapeutics00103.00
Fusion Pharmaceuticals00503.00

Brainstorm Cell Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 246.82%. Fusion Pharmaceuticals has a consensus target price of $24.3333, suggesting a potential upside of 120.61%. Given Brainstorm Cell Therapeutics' higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Fusion Pharmaceuticals.

Valuation & Earnings

This table compares Brainstorm Cell Therapeutics and Fusion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A

Profitability

This table compares Brainstorm Cell Therapeutics and Fusion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%
Fusion PharmaceuticalsN/A-26.14%-18.26%

Summary

Fusion Pharmaceuticals beats Brainstorm Cell Therapeutics on 5 of the 7 factors compared between the two stocks.

Harpoon Therapeutics (NASDAQ:HARP) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Valuation and Earnings

This table compares Harpoon Therapeutics and Brainstorm Cell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harpoon Therapeutics$5.78 million79.61$-55,570,000.00($2.55)-7.11
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Harpoon Therapeutics. Harpoon Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Harpoon Therapeutics and Brainstorm Cell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harpoon Therapeutics-434.74%-68.32%-29.45%
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%

Risk & Volatility

Harpoon Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

79.0% of Harpoon Therapeutics shares are held by institutional investors. Comparatively, 21.6% of Brainstorm Cell Therapeutics shares are held by institutional investors. 34.9% of Harpoon Therapeutics shares are held by insiders. Comparatively, 22.1% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Harpoon Therapeutics and Brainstorm Cell Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harpoon Therapeutics00703.00
Brainstorm Cell Therapeutics00103.00

Harpoon Therapeutics presently has a consensus target price of $31.5714, suggesting a potential upside of 74.14%. Brainstorm Cell Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 246.82%. Given Brainstorm Cell Therapeutics' higher probable upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Harpoon Therapeutics.

Summary

Harpoon Therapeutics beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

AVROBIO (NASDAQ:AVRO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Volatility & Risk

AVROBIO has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for AVROBIO and Brainstorm Cell Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVROBIO03502.63
Brainstorm Cell Therapeutics00103.00

AVROBIO presently has a consensus target price of $27.8333, suggesting a potential upside of 142.87%. Brainstorm Cell Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 246.82%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than AVROBIO.

Earnings & Valuation

This table compares AVROBIO and Brainstorm Cell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVROBION/AN/A$-72,960,000.00($2.66)-4.31
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26

AVROBIO is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

86.7% of AVROBIO shares are owned by institutional investors. Comparatively, 21.6% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 4.8% of AVROBIO shares are owned by insiders. Comparatively, 22.1% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AVROBIO and Brainstorm Cell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVROBION/A-51.33%-47.65%
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%

Summary

Brainstorm Cell Therapeutics beats AVROBIO on 6 of the 11 factors compared between the two stocks.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Cellular Biomedicine Group (NASDAQ:CBMG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Brainstorm Cell Therapeutics and Cellular Biomedicine Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Brainstorm Cell Therapeutics00103.00
Cellular Biomedicine Group01002.00

Brainstorm Cell Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 246.82%. Cellular Biomedicine Group has a consensus price target of $19.00, suggesting a potential downside of 3.80%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Cellular Biomedicine Group.

Risk & Volatility

Brainstorm Cell Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.

Profitability

This table compares Brainstorm Cell Therapeutics and Cellular Biomedicine Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%
Cellular Biomedicine GroupN/A-144.80%-61.68%

Institutional and Insider Ownership

21.6% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 22.0% of Cellular Biomedicine Group shares are owned by institutional investors. 22.1% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Brainstorm Cell Therapeutics and Cellular Biomedicine Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26
Cellular Biomedicine Group$340,000.001,131.44$-49,980,000.00N/AN/A

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Cellular Biomedicine Group.

Summary

Brainstorm Cell Therapeutics beats Cellular Biomedicine Group on 6 of the 11 factors compared between the two stocks.

Freeline Therapeutics (NASDAQ:FRLN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Freeline Therapeutics and Brainstorm Cell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Freeline TherapeuticsN/AN/AN/AN/AN/A
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26

Profitability

This table compares Freeline Therapeutics and Brainstorm Cell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Freeline TherapeuticsN/AN/AN/A
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%

Analyst Recommendations

This is a breakdown of recent recommendations for Freeline Therapeutics and Brainstorm Cell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Freeline Therapeutics01502.83
Brainstorm Cell Therapeutics00103.00

Freeline Therapeutics presently has a consensus price target of $26.00, suggesting a potential upside of 79.43%. Brainstorm Cell Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 246.82%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Freeline Therapeutics.

Insider and Institutional Ownership

38.5% of Freeline Therapeutics shares are held by institutional investors. Comparatively, 21.6% of Brainstorm Cell Therapeutics shares are held by institutional investors. 22.1% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Freeline Therapeutics beats Brainstorm Cell Therapeutics on 4 of the 7 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Institutional & Insider Ownership

21.6% of Brainstorm Cell Therapeutics shares are held by institutional investors. 22.1% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Opthea and Brainstorm Cell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
Brainstorm Cell TherapeuticsN/AN/A$-23,250,000.00($1.06)-3.26

Profitability

This table compares Opthea and Brainstorm Cell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
Brainstorm Cell TherapeuticsN/A-339.86%-144.74%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Opthea and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
Brainstorm Cell Therapeutics00103.00

Opthea currently has a consensus price target of $36.00, suggesting a potential upside of 321.05%. Brainstorm Cell Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 246.82%. Given Opthea's higher probable upside, equities analysts clearly believe Opthea is more favorable than Brainstorm Cell Therapeutics.

Summary

Opthea beats Brainstorm Cell Therapeutics on 4 of the 7 factors compared between the two stocks.


Brainstorm Cell Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.03-2.0%$460.24 millionN/A0.00
HARP
Harpoon Therapeutics
1.5$18.13-2.6%$460.14 million$5.78 million-8.51Upcoming Earnings
AVROBIO logo
AVRO
AVROBIO
1.7$11.46-1.2%$417.73 millionN/A-3.47Upcoming Earnings
Analyst Report
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$14.49-5.6%$375.60 millionN/A0.00Analyst Report
Gap Up
Opthea logo
OPT
Opthea
1.5$8.55-6.5%$360.88 millionN/A0.00High Trading Volume
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.41-2.3%$348.31 million$96.12 million-12.97Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.54-2.6%$341.10 millionN/A0.00Upcoming Earnings
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.15-6.2%$339.03 million$250,000.00-3.27
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.57-0.1%$336.94 millionN/A0.00Upcoming Earnings
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.16-0.5%$321.86 million$2.91 million-2.15Earnings Announcement
Analyst Revision
Gap Down
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-0.6%$313.91 million$8.15 million-1.45Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.50-7.1%$310.94 millionN/A-5.47
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$14.30-4.1%$308.18 millionN/A0.00Upcoming Earnings
Gap Down
Surface Oncology logo
SURF
Surface Oncology
1.3$7.36-1.9%$299.38 million$15.36 million-11.15
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.06-0.2%$294.74 millionN/A-3.73Upcoming Earnings
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.26-0.9%$279.49 million$4.13 million-5.01Upcoming Earnings
News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$11.26-4.1%$270.86 millionN/A-8.22
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.86-2.8%$249.84 millionN/A-4.91Upcoming Earnings
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$5.09-18.3%$215.09 million$1.45 million-1.79High Trading Volume
Increase in Short Interest
Analyst Revision
Gap Down
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.50-0.5%$207.10 million$104.39 million-3.35
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.66-4.7%$198.79 million$2.45 million-2.19Analyst Report
Axcella Health logo
AXLA
Axcella Health
1.6$5.28-1.5%$198.22 millionN/A-2.46
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.15-1.8%$197.39 millionN/A-5.70Gap Down
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.04-2.5%$192.88 million$29.35 million-2.37Upcoming Earnings
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.28-0.7%$189.30 millionN/A-8.88Upcoming Earnings
Genfit logo
GNFT
Genfit
1.3$4.87-0.6%$189.24 million$45.88 million-2.47Gap Down
INmune Bio logo
INMB
INmune Bio
1.5$13.12-9.1%$176.44 millionN/A-13.53Earnings Announcement
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.5$13.20-1.6%$168.68 million$2.33 million0.00
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.04-1.1%$161.19 millionN/A-2.05Gap Up
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.05-1.6%$157.53 millionN/A0.00Upcoming Earnings
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.51-0.1%$154.89 millionN/A-2.97Earnings Announcement
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.87-2.5%$153.55 million$20,000.000.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$14.53-0.8%$148.58 millionN/A0.00High Trading Volume
Champions Oncology logo
CSBR
Champions Oncology
1.1$11.02-6.4%$147.33 million$32.12 million-84.77Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.64-1.9%$141.29 millionN/A-1.82
Dyadic International logo
DYAI
Dyadic International
1.3$5.13-3.5%$140.98 million$1.68 million-15.09
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.56-2.6%$124.86 million$23.05 million-2.03Earnings Announcement
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.9$8.03-2.4%$124.30 million$3 million-2.58
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.40-3.8%$115.30 million$20.92 million-1.38
AIM
AIM ImmunoTech
1.7$2.01-2.0%$81.78 million$140,000.000.00Upcoming Earnings
News Coverage
Gap Down
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$10.84-7.1%$79.49 millionN/A0.00
PolarityTE logo
PTE
PolarityTE
1.4$1.28-0.8%$76.97 million$5.65 million-0.77Upcoming Earnings
BBI
Brickell Biotech
1.1$1.14-2.6%$75.96 million$7.92 million-0.47
Organovo logo
ONVO
Organovo
0.7$10.27-4.0%$73.09 million$2.20 million0.00Decrease in Short Interest
WINT
Windtree Therapeutics
2.0$3.99-8.0%$67.52 million$200,000.00-1.66News Coverage
Gap Down
GENE
Genetic Technologies
0.4$4.11-4.1%$61.73 million$10,000.000.00
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.52-3.3%$58.20 millionN/A-1.21Upcoming Earnings
Gap Down
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.85-0.8%$55.80 millionN/A0.00Gap Up
This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.